BCL2 and lymphoma: The magnitude of epigenetic heterogeneity was greater in the malignant cells (median AICDA signature VavP-Bcl2+Aicda IQR: 19.2%; median AICDA signature GCB WT IQR: 17.35%; Wilcoxon's P < 1e−300), which is expected since AICDA expression is transient in normal GCs but presumably sustained for longer periods in the lymphomas.